Drew Watson

SVP, Clinical Studies & Biostatistics at CellMax Life

Dr Watson is responsible for clinical studies at CellMax Life. He is a highly accomplished senior executive with over 30 years of success in biostatistics and computational biology at Invitae, Genomic Health, Incyte Genomics, and Chiron Corporation. At Genomic Health, he led the pivotal clinical trial for the molecular diagnostic, Oncotype DX for breast cancer recurrence risk assessment, leading to its coverage by the Centers of Medicare and Medicaid (CMS). He has published extensively in the area of biostatistics, oncology and genomics, and is a holder of multiple key U.S. patents in genomics, algorithm development, and personalized medicine. Dr Watson earned a B.S. in Statistics from California State University East Bay, an M.S. in Computational Statistics from Stanford University, an M.B.A. in Strategic Management from Golden State University, and a PhD in Biostatistics from University of California Los Angeles (UCLA).

Location

San Francisco, United States

Links


Org chart

No direct reports

Teams


Offices

This person is not in any offices


CellMax Life

CellMax Life is a leading cancer diagnostics company whose mission is to transform how cancer is diagnosed and managed with globally affordable non-invasive tests for early cancer detection and management.


Industries

Employees

51-200

Links